GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sprint Bioscience AB (OSTO:SPRINT) » Definitions » Cyclically Adjusted PS Ratio

Sprint Bioscience AB (OSTO:SPRINT) Cyclically Adjusted PS Ratio : 0.47 (As of Sep. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sprint Bioscience AB Cyclically Adjusted PS Ratio?

As of today (2024-09-21), Sprint Bioscience AB's current share price is kr1.17. Sprint Bioscience AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was kr2.48. Sprint Bioscience AB's Cyclically Adjusted PS Ratio for today is 0.47.

The historical rank and industry rank for Sprint Bioscience AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:SPRINT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.2   Med: 0.52   Max: 0.96
Current: 0.5

During the past years, Sprint Bioscience AB's highest Cyclically Adjusted PS Ratio was 0.96. The lowest was 0.20. And the median was 0.52.

OSTO:SPRINT's Cyclically Adjusted PS Ratio is ranked better than
91.38% of 464 companies
in the Biotechnology industry
Industry Median: 5.355 vs OSTO:SPRINT: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sprint Bioscience AB's adjusted revenue per share data for the three months ended in Jun. 2024 was kr0.239. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr2.48 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sprint Bioscience AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sprint Bioscience AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sprint Bioscience AB Cyclically Adjusted PS Ratio Chart

Sprint Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.67

Sprint Bioscience AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.79 0.67 0.41 0.59

Competitive Comparison of Sprint Bioscience AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sprint Bioscience AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sprint Bioscience AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's Cyclically Adjusted PS Ratio falls into.



Sprint Bioscience AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sprint Bioscience AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.17/2.48
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Sprint Bioscience AB's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=0.239/132.7160*132.7160
=0.239

Current CPI (Jun. 2024) = 132.7160.

Sprint Bioscience AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.000 100.161 0.000
201412 0.000 100.225 0.000
201503 0.000 99.950 0.000
201506 0.000 99.995 0.000
201509 0.444 100.228 0.588
201512 0.437 100.276 0.578
201603 0.359 100.751 0.473
201606 1.613 101.019 2.119
201609 0.878 101.138 1.152
201612 1.025 102.022 1.333
201703 0.975 102.022 1.268
201706 1.011 102.752 1.306
201709 0.257 103.279 0.330
201712 0.264 103.793 0.338
201803 1.738 103.962 2.219
201806 0.008 104.875 0.010
201809 0.000 105.679 0.000
201812 0.015 105.912 0.019
201903 0.361 105.886 0.452
201906 1.625 106.742 2.020
201909 0.306 107.214 0.379
201912 0.347 107.766 0.427
202003 0.353 106.563 0.440
202006 0.320 107.498 0.395
202009 0.263 107.635 0.324
202012 0.094 108.296 0.115
202103 0.001 108.360 0.001
202106 0.000 108.928 0.000
202109 0.897 110.338 1.079
202112 0.017 112.486 0.020
202203 0.001 114.825 0.001
202206 0.000 118.384 0.000
202209 0.000 122.296 0.000
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.001 129.407 0.001
202309 0.567 130.224 0.578
202312 0.156 131.912 0.157
202403 0.256 132.205 0.257
202406 0.239 132.716 0.239

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sprint Bioscience AB  (OSTO:SPRINT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sprint Bioscience AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sprint Bioscience AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sprint Bioscience AB Business Description

Traded in Other Exchanges
Address
Halsovagen 7, Floor 8, Elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.

Sprint Bioscience AB Headlines

No Headlines